$0.07
Biocept is a diagnostics & research business based in the US. Biocept shares (BIOC) are listed on the NASDAQ and all prices are listed in US Dollars. Biocept employs 50 staff and has a trailing 12-month revenue of around $1.4 million.
Our top picks for where to buy Biocept stock
How to buy Biocept stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BIOC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Biocept stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Biocept stock price (NASDAQ: BIOC)
Use our graph to track the performance of BIOC stocks over time.Biocept shares at a glance
Latest market close | $0.07 |
---|---|
52-week range | $0.03 - $1.85 |
50-day moving average | $0.95 |
200-day moving average | $5.33 |
Wall St. target price | $4.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-48.17 |
Is it a good time to buy Biocept stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biocept price performance over time
Historical closes compared with the close of $0.0698 from 2023-12-26
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-07) | -91.69% |
---|---|
2 years (2022-09-07) | -92.57% |
3 years (2021-09-07) | 3.64 |
5 years (2019-09-06) | 8.748 |
Biocept financials
Revenue TTM | $1.4 million |
---|---|
Gross profit TTM | $-2,582,000 |
Return on assets TTM | -51.65% |
Return on equity TTM | -186.94% |
Profit margin | 0% |
Book value | $0.12 |
Market Capitalization | $1.1 million |
TTM: trailing 12 months
Biocept share dividends
We're not expecting Biocept to pay a dividend over the next 12 months.
Have Biocept's shares ever split?
Biocept's shares were split on a 1:30 basis on 16 May 2023. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biocept shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Biocept shares which in turn could have impacted Biocept's share price.
Biocept share price volatility
Over the last 12 months, Biocept's shares have ranged in value from as little as $0.0251 up to $1.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biocept's is 0.595. This would suggest that Biocept's shares are less volatile than average (for this exchange).
Biocept overview
Biocept, Inc. , a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients.
Frequently asked questions
nullWhat percentage of Biocept is owned by insiders or institutions?
Currently 9.209% of Biocept shares are held by insiders and 1.982% by institutions. How many people work for Biocept?
Latest data suggests 50 work at Biocept. When does the fiscal year end for Biocept?
Biocept's fiscal year ends in December. Where is Biocept based?
Biocept's address is: 9955 Mesa Rim Road, San Diego, CA, United States, 92121 What is Biocept's ISIN number?
Biocept's international securities identification number is: US09072V5012 What is Biocept's CUSIP number?
Biocept's Committee on Uniform Securities Identification Procedures number is: 09072V402
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question